Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Frequency Therapeutics shares plummet after FX-322 Phase 2b failure

By Brian Buntz | February 13, 2023

Frequency TherapeuticsFrequency Therapeutics (Nasdaq:FREQ) shares were down more than 80% on Monday afternoon after the company announced the failure of the Phase 2b study for FX-322, its lead candidate drug for hearing loss. As a result, the Lexington, Massachusetts-based biotech company will discontinue its hearing loss program and cut its workforce by 55%.

It says its cost savings measures will extend its runway into 2025.

In late 2022, Otonomy, another neurotology biopharma once listed on Nasdaq, said it had decided to dissolve its business and liquidate its assets.

FX-322 had no statistically significant difference over placebo

Frequency Therapeutics said the Phase 2b study showed that the drug FX-322 did not improve speech perception more than placebo. The company will also discontinue its second program for sudden or noise-induced sensorineural hearing loss, FX-345.

FX-322 did not meet its primary endpoint or any of the study’s secondary endpoints. The safety profile of FX-322 was favorable and no adverse events were associated with treatment.

Frequency was founded to develop a new category of therapeutic drugs designed to stimulate existing progenitor cells in the body to promote production of functional and healthy tissues and organs.

Refocusing on MS

The company said it would focus its resources on developing novel therapeutics for inducing remyelination in multiple sclerosis (MS) patients. Frequency reports having discovered a novel target related to myelination. It has found multiple chemical entities that induce strong remyelination after demyelination in adult animals. This MS program is separate from the hearing program and has its own molecular target, mechanism, cell population and drug candidates.

Frequency hopes to begin its clinical program for remyelination in the first half of 2024.

The company also said that its CEO, David Lucchino, has taken temporary medical leave as he was hospitalized with bacterial meningitis. He is expected to fully recover and return to work in the near future. In the interim, Chris Loose, the company’s chief scientific officer, will serve as the interim CEO.

Frequency was founded in 2014.


Filed Under: ENT drugs
Tagged With: Frequency Therapeutics, FX-322
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Otonomy
Otonomy gives up on experimental tinnitus drug after disappointing Phase 2 trial
Pfizer
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Decibel Therapeutics
Decibel Therapeutics touts progress with lead gene therapy product candidate DB-OTO
Otonomy
Investigational tinnitus drug shows promise in Phase 1/2 study
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE